Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin + Ocrelizumab in Progressive Primary Multiple Sclerosis
NCT03540485Phase 2Terminated
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Nov 2019
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of melatonin in primary progressive multiple sclerosis (PPMS), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Started Nov 2019; status: terminated.
02
Drugs
melatonin
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NCT03540485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03540485.